Vascular and Immunobiology of the Circulatory Sphingosine 1-Phosphate Gradient

Annual Review of Physiology

Volumn 79, Issue , 2017, Pages 67-91

  Yanagida, Keisuke ^a   Hla, Timothy ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; G protein coupled receptor; HDL; Immune cell trafficking; Lipid chaperones; Lipid mediators; Sphingolipid; Vascular biology

Indexed keywords

CHAPERONE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR 2; SPHINGOSINE 1 PHOSPHATE RECEPTOR 3; SPHINGOSINE 1 PHOSPHATE RECEPTOR 4; SPHINGOSINE 1 PHOSPHATE RECEPTOR 5; UNCLASSIFIED DRUG; VASODILATOR AGENT; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ANGIOGENESIS; BLOOD BRAIN BARRIER; BLOOD VESSEL TONE; CARDIOVASCULAR FUNCTION; CELL ACTIVATION; CELL MATURATION; CELL MIGRATION; CELLULAR PARAMETERS; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; ENZYMATIC DEGRADATION; ERYTHROCYTE; HUMAN; IMMUNOBIOLOGY; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; LYMPH FLOW; MECHANOTRANSDUCTION; MICROENVIRONMENT; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SECRETION; REPORTER GENE; REVIEW; SHEAR STRESS; T LYMPHOCYTE; VASCULAR BIOLOGY; VASCULARIZATION; VENULE; ANALOGS AND DERIVATIVES; ANIMAL; CARDIOVASCULAR SYSTEM; HOMEOSTASIS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR SYSTEM; HOMEOSTASIS; HUMANS; LYSOPHOSPHOLIPIDS; SPHINGOSINE;

EID: 85013030381     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021014-071635     Document Type: Review

References (159)

1. Armulik A, Genove G, Betsholtz C. 2011. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 21:193-215
2. Kihara A. 2014. Sphingosine 1-phosphate is a key metabolite linking sphingolipids to glycerophospholipids. Biochim. Biophys. Acta 1841:766-72
3. Hla T. 2005. Genomic insights into mediator lipidomics. Prostaglandins Other Lipid Mediat. 77:197-209
4. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. 2005. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309:1735-39
5. Hla T, Venkataraman K, Michaud J. 2008. The vascular S1P gradient-cellular sources and biological significance. Biochim. Biophys. Acta 1781:477-82
6. Givens C, Tzima E. 2012. S1P1 bridges mechanotransduction and angiogenesis during vascular development. Dev. Cell 23:451-52
7. Tarbell JM, Simon SI, Curry FR. 2014. Mechanosensing at the vascular interface. Annu. Rev. Biomed. Eng. 16:505-32
8. Schwab SR,Cyster JG. 2007. Finding a way out: lymphocyte egress from lymphoid organs. Nat. Immunol. 8:1295-301
9. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, et al. 2007. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316:295-98
10. Xiong Y, Yang P, Proia RL, Hla T. 2014. Erythrocyte-derived sphingosine 1-phosphate is essential for vascular development. J. Clin. Investig. 124:4823-28
11. Lee YM, Venkataraman K, Hwang SI, Han DK, Hla T. 2007. A novel method to quantify sphingosine 1-phosphate by immobilized metal affinity chromatography (IMAC). Prostaglandins Other Lipid Mediat. 84:154-62
12. Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, et al. 2008. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ. Res. 102:669-76
13. Yatomi Y, Igarashi Y, Yang L, Hisano N, Qi R, et al. 1997. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J. Biochem. 121:969-73
14. Yatomi Y, Ruan F, Hakomori S, Igarashi Y. 1995. Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood 86:193-202
15. Yatomi Y, Yamamura S, Ruan F, Igarashi Y. 1997. Sphingosine 1-phosphate induces platelet activation through an extracellular action and shares a platelet surface receptor with lysophosphatidic acid. J. Biol. Chem. 272:5291-97
16. Ikeda M, Kihara A, Igarashi Y. 2004. Sphingosine-1-phosphate lyase SPL is an endoplasmic reticulumresident, integral membrane protein with the pyridoxal 5-phosphate binding domain exposed to the cytosol. Biochem. Biophys. Res. Commun. 325:338-43
17. Jonnalagadda D, Sunkara M, Morris AJ, Whiteheart SW. 2014. Granule-mediated release of sphingosine-1-phosphate by activated platelets. Biochim. Biophys. Acta 1841:1581-89
18. Urtz N, Gaertner F, von Bruehl ML, Chandraratne S, Rahimi F, et al. 2015. Sphingosine 1-phosphate produced by sphingosine kinase 2 intrinsically controls platelet aggregation in vitro and in vivo. Circ. Res. 117:376-87
19. Allende ML, Sasaki T, Kawai H, Olivera A,Mi Y, et al. 2004. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem. 279:52487-92
20. Zemann B, Kinzel B, Müller M, Reuschel R, Mechtcheriakova D, et al. 2006. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107:1454-58
21. Olivera A, Mizugishi K, Tikhonova A, Ciaccia L, Odom S, et al. 2007. The sphingosine kinasesphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity 26:287-97
22. Kharel Y, Mathews TP, Gellett AM, Tomsig JL, Kennedy PC, et al. 2011. Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate. Biochem. J. 440:345-53
23. Kharel Y, Raje M, Gao M, Gellett AM, Tomsig JL, et al. 2012. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. Biochem. J. 447:149-57
24. Sensken SC, Bode C, Nagarajan M, Peest U, Pabst O, Gräler MH. 2010. Redistribution of sphingosine 1-phosphate by sphingosine kinase 2 contributes to lymphopenia. J. Immunol. 184:4133-42
25. Olivera A, Eisner C, Kitamura Y, Dillahunt S, Allende L, et al. 2010. Sphingosine kinase 1 and sphingosine-1-phosphate receptor 2 are vital to recovery from anaphylactic shock inmice. J. Clin. Investig. 120:1429-40
26. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, et al. 2013. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 23:107-20
27. Kharel Y, Morris EA, Congdon MD,Thorpe SB, Tomsig JL, et al. 2015. Sphingosine kinase 2 inhibition and blood sphingosine 1-phosphate levels. J. Pharmacol. Exp. Ther. 355:23-31
28. Takuwa N, Ohkura S, Takashima S, Ohtani K, Okamoto Y, et al. 2010. S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc. Res. 85:484-93
29. Kawahara A, Nishi T, Hisano Y, Fukui H, Yamaguchi A, Mochizuki N. 2009. The sphingolipid transporter Spns2 functions in migration of zebrafish myocardial precursors. Science 323:524-27
30. Osborne N, Brand-Arzamendi K, Ober EA, Jin SW, Verkade H, et al. 2008. The spinster homolog, two of hearts, is required for sphingosine 1-phosphate signaling in zebrafish. Curr. Biol. 18:1882-88
31. Fukuhara S, Simmons S, Kawamura S, Inoue A, Orba Y, et al. 2012. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J. Clin. Investig. 122:1416-26
32. Hisano Y, Kobayashi N, Yamaguchi A, Nishi T. 2012. Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells. PLOS ONE 7:e38941
33. Mendoza A, Bréart B, Ramos-Perez WD, Pitt LA, Gobert M, et al. 2012. The transporter Spns2 is required for secretion of lymph but not plasma sphingosine-1-phosphate. Cell Rep. 2:1104-10
34. Nagahashi M, Kim EY, Yamada A, Ramachandran S, Allegood JC, et al. 2013. Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network. FASEB J. 27:1001-11
35. Honig SM, Fu S, Mao X, Yopp A, Gunn MD, et al. 2003. FTY720 stimulates multidrug transporterand cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J. Clin. Investig. 111:627-37
36. Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, Spiegel S. 2006. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. PNAS 103:16394-99
37. Kobayashi N, Nishi T, Hirata T, Kihara A, Sano T, et al. 2006. Sphingosine 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated manner. J. Lipid Res. 47:614-21
38. Sato K, Malchinkhuu E, Horiuchi Y, Mogi C, Tomura H, et al. 2007. Critical role of ABCA1 transporter in sphingosine 1-phosphate release from astrocytes. J. Neurochem. 103:2610-19
39. Takabe K, Kim RH, Allegood JC, Mitra P, Ramachandran S, et al. 2010. Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J. Biol. Chem. 285:10477-86
40. Hisano Y, Kobayashi N, Kawahara A, Yamaguchi A, Nishi T. 2011. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. J. Biol. Chem. 286:1758-66
41. Bode C, Sensken SC, PeestU, BeutelG, Thol F, et al. 2010. Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J. Cell. Biochem. 109:1232-43
42. Kimura T, Tomura H,Mogi C, Kuwabara A, Damirin A, et al. 2006. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 281:37457-67
43. Argraves KM,Gazzolo PJ,Groh EM, Wilkerson BA, Matsuura BS, et al. 2008. High density lipoproteinassociated sphingosine 1-phosphate promotes endothelial barrier function. J. Biol. Chem. 283:25074-81
44. Wilkerson BA, Grass GD, Wing SB, Argraves WS, Argraves KM. 2012. Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J. Biol. Chem. 287:44645-53
45. Blaho VA, Galvani S, Engelbrecht E, Liu C, Swendeman SL, et al. 2015. HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. Nature 523:342-46
46. Galvani S, Sanson M, Blaho VA, Swendeman SL, Obinata H, et al. 2015. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci. Signal. 8:ra79
47. Murata N, Sato K, Kon J, Tomura H, Yanagita M, et al. 2000. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem. J. 352(Pt. 3):809-15
48. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnström J, et al. 2011. Endotheliumprotective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. PNAS 108:9613-18
49. Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlbäck B. 2006. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J. Lipid Res. 47:1833-43
50. Kurano M, Tsukamoto K, Ohkawa R, Hara M, Iino J, et al. 2013. Liver involvement in sphingosine 1-phosphate dynamism revealed by adenoviral hepatic overexpression of apolipoproteinM. Atherosclerosis 229:102-9
51. Sevvana M, Ahnström J, Egerer-Sieber C, LangeHA, Dahlbäck B, Muller YA. 2009. Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoproteinM. J. Mol. Biol. 393:920-36
52. Yatomi Y, Ohmori T, Rile G, Kazama F, Okamoto H, et al. 2000. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 96:3431-38
53. Weber C, Krueger A, Munk A, Bode C, Van Veldhoven PP, Gräler MH. 2009. Discontinued postnatal thymocyte development in sphingosine 1-phosphate-lyase-deficient mice. J. Immunol. 183:4292-301
54. Vogel P,DonovielMS, Read R, HansenGM,Hazlewood J, et al. 2009. Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions. PLOS ONE 4:e4112
55. Bektas M, AllendeML, LeeBG, ChenW,AmarMJ, et al. 2010. Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver. J. Biol. Chem. 285:10880-89
56. Ito K, Anada Y, Tani M, Ikeda M, Sano T, et al. 2007. Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem. Biophys. Res. Commun. 357:212-17
57. Mandala SM. 2001. Sphingosine-1-phosphate phosphatases. Prostaglandins Other Lipid Mediat. 64:143-56
58. Pyne S, Long JS, Ktistakis NT, Pyne NJ. 2005. Lipid phosphate phosphatases and lipid phosphate signalling. Biochem. Soc. Trans. 33:1370-74
59. Bréart B, Ramos-Perez WD, Mendoza A, Salous AK,Gobert M, et al. 2011. Lipid phosphate phosphatase 3 enables efficient thymic egress. J. Exp. Med. 208:1267-78
60. Eilken HM, Adams RH. 2010. Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr. Opin. Cell Biol. 22:617-25
61. Bergstrand CG, Czar B. 1956. Demonstration of a new protein fraction in serum from the human fetus. Scand. J. Clin. Lab. Investig. 8:174
62. Tilghman SM, Belayew A. 1982. Transcriptional control of the murine albumin/alpha-fetoprotein locus during development. PNAS 79:5254-57
63. Zhang XY, Jiao GQ, Hurtig M, Dong X, Zheng L, et al. 2004. Expression pattern of apolipoprotein M during mouse and human embryogenesis. Acta Histochem. 106:123-28
64. Gabant P, Forrester L, Nichols J, Van Reeth T, De Mees C, et al. 2002. Alpha-fetoprotein, the major fetal serum protein, is not essential for embryonic development but is required for female fertility. PNAS 99:12865-70
65. MizugishiK,Yamashita T, OliveraA,MillerGF, Spiegel S,Proia RL. 2005. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 25:11113-21
66. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, et al. 2000. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Investig. 106:951-61
67. Allende ML, Yamashita T, Proia RL. 2003. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 102:3665-67
68. Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, et al. 2002. Marked perinatal lethality and cellular signaling deficits inmice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. J. Biol. Chem. 277:25152-59
69. Kono M, Mi Y, Liu Y, Sasaki T, AllendeML, et al. 2004. The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J. Biol. Chem. 279:29367-73
70. Pham TH, Baluk P, Xu Y,Grigorova I, Bankovich AJ, et al. 2010. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J. Exp. Med. 207:17-27
71. Sloop CH, Dory L, Roheim PS. 1987. Interstitial fluid lipoproteins. J. Lipid Res. 28:225-37
72. Blaho VA, Hla T. 2011. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem. Rev. 111:6299-320
73. Obinata H, Hla T. 2012. Sphingosine 1-phosphate in coagulation and inflammation. Semin. Immunopathol. 34:73-91
74. Blaho VA, Hla T. 2014. An update on the biology of sphingosine 1-phosphate receptors. J. Lipid Res. 55:1596-608
75. Proia RL, Hla T. 2015. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J. Clin. Investig. 125:1379-87
76. Du W, Takuwa N, Yoshioka K, Okamoto Y, Gonda K, et al. 2010. S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice. Cancer Res. 70:772-81
77. Liu CH, Thangada S, Lee MJ, Van Brocklyn JR, Spiegel S, Hla T. 1999. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol. Biol. Cell 10:1179-90
78. Watterson KR, JohnstonE,ChalmersC,ProninA,Cook SJ, et al. 2002. Dual regulation of EDG1/S1P(1) receptor phosphorylation and internalization by protein kinaseCand G-protein-coupled receptor kinase. J. Biol. Chem. 277:5767-77
79. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, et al. 2007. Immunosuppressive and antiangiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 282:9082-89
80. Zachariah MA, Cyster JG. 2010. Neural crest-derived pericytes promote egress of mature thymocytes at the corticomedullary junction. Science 328:1129-35
81. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, et al. 2003. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. 278:47281-90
82. Kharel Y, Lee S, Snyder AH, Sheasley-O'Neill SL, Morris MA, et al. 2005. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J. Biol. Chem. 280:36865-72
83. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, et al. 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362:402-15
84. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, et al. 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362:387-401
85. Mandala S, Hajdu R, Bergstrom J,Quackenbush E, Xie J, et al. 2002. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-49
86. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, et al. 2002. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277:21453-57
87. Gräler MH, Goetzl EJ. 2004. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 18:551-53
88. Oo ML, Chang SH, Thangada S, Wu MT, Rezaul K, et al. 2011. Engagement of S1P(1)-degradative mechanisms leads to vascular leak in mice. J. Clin. Investig. 121:2290-300
89. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, et al. 2004. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor. Nature 427:355-60
90. Barnea G, Strapps W, Herrada G, Berman Y, Ong J, et al. 2008. The genetic design of signaling cascades to record receptor activation. PNAS 105:64-69
91. Kono M, Tucker AE, Tran J, Bergner JB, Turner EM, Proia RL. 2014. Sphingosine-1-phosphate receptor 1 reporter mice reveal receptor activation sites in vivo. J. Clin. Investig. 124:2076-86
92. Ramos-PerezWD, Fang V, Escalante-Alcalde D, CammerM, Schwab SR. 2015. A map of the distribution of sphingosine 1-phosphate in the spleen. Nat. Immunol. 16:1245-52
93. Christensen PM, Liu CH, Swendeman SL, Obinata H, Qvortrup K, et al. 2016. Impaired endothelial barrier function in apolipoproteinM-deficient mice is dependent on sphingosine-1-phosphate receptor. FASEB J. 30:2351-59
94. Shenoy SK, Lefkowitz RJ. 2011. Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 32:521-33
95. Tatematsu S, Francis SA,Natarajan P, Rader DJ, Saghatelian A, et al. 2013. Endothelial lipase is a critical determinant of high-density lipoprotein-stimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium. Arterioscler. Thromb. Vasc. Biol. 33:1788-94
96. Takada Y, Kato C, Kondo S, Korenaga R, Ando J. 1997. Cloning of cDNAs encodingGprotein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem. Biophys. Res. Commun. 240:737-41
97. Hughes SK, Wacker BK, Kaneda MM, Elbert DL. 2005. Fluid shear stress modulates cell migration induced by sphingosine 1-phosphate and vascular endothelial growth factor. Ann. Biomed. Eng. 33:1003-14
98. Aoki S, Osada M, Kaneko M, Ozaki Y, Yatomi Y. 2007. Fluid shear stress enhances the sphingosine 1-phosphate responses in cell-cell interactions between platelets and endothelial cells. Biochem. Biophys. Res. Commun. 358:1054-57
99. Jung B, Obinata H, Galvani S, Mendelson K, Ding BS, et al. 2012. Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development. Dev. Cell 23:600-10
100. Carlson CM, Endrizzi BT, Wu J, Ding X, Weinreich MA, et al. 2006. Krüppel-like factor 2 regulates thymocyte and T-cell migration. Nature 442:299-302
101. Bai A, Hu H, Yeung M, Chen J. 2007. Krüppel-like factor 2 controls T cell trafficking by activating L-selectin (CD62L) and sphingosine-1-phosphate receptor 1 transcription. J. Immunol. 178:7632-39
102. Weinreich MA, Takada K, Skon C, Reiner SL, Jameson SC, Hogquist KA. 2009. KLF2 transcriptionfactor deficiency in T cells results in unrestrained cytokine production and upregulation of bystander chemokine receptors. Immunity 31:122-30
103. Dekker RJ, Boon RA, Rondaij MG, Kragt A, Volger OL, et al. 2006. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood 107:4354-63
104. Parmar KM, Larman HB, Dai G, Zhang Y, Wang ET, et al. 2006. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J. Clin. Investig. 116:49-58
105. Kuo CT, Veselits ML, Barton KP, Lu MM, Clendenin C, Leiden JM. 1997. The LKLF transcription factor is required for normal tunica media formation and blood vessel stabilization during murine embryogenesis. Genes Dev. 11:2996-3006
106. Hahn C, Schwartz MA. 2009. Mechanotransduction in vascular physiology and atherogenesis. Nat. Rev. Mol. Cell Biol. 10:53-62
107. Ishii I, Friedman B, Ye X, Kawamura S, McGiffert C, et al. 2001. Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J. Biol. Chem. 276:33697-704
108. Gaengel K, Niaudet C, Hagikura K, Laviña B, Muhl L, et al. 2012. The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. Dev. Cell 23:587-99
109. Chae SS, Paik JH, Allende ML, Proia RL, Hla T. 2004. Regulation of limb development by the sphingosine 1-phosphate receptor S1p1/EDG-1 occurs via the hypoxia/VEGF axis. Dev. Biol. 268:441-47
110. Ben Shoham A,MalkinsonG,Krief S, Shwartz Y, Ely Y, et al. 2012. S1P1 inhibits sprouting angiogenesis during vascular development. Development 139:3859-69
111. Phng LK, Gerhardt H. 2009. Angiogenesis: a team effort coordinated by notch. Dev. Cell 16:196-208
112. Paik JH, Skoura A, Chae SS, Cowan AE, Han DK, et al. 2004. Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev. 18:2392-403
113. Lindahl P, Johansson BR, Leveen P, Betsholtz C. 1997. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242-45
114. Hellström M, Kalén M, Lindahl P, Abramsson A, Betsholtz C. 1999. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126:3047-55
115. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, et al. 1999. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99:301-12
116. Xiong Y, Hla T. 2014. S1P control of endothelial integrity. Curr. Top. Microbiol. Immunol. 378:85-105
117. Li X, Stankovic M, Bonder CS, Hahn CN, Parsons M, et al. 2008. Basal and angiopoietin-1-mediated endothelial permeability is regulated by sphingosine kinase-1. Blood 111:3489-97
118. Camerer E, Regard JB, Cornelissen I, Srinivasan Y,DuongDN, et al. 2009. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J. Clin. Investig. 119:1871-79
119. Sanna MG,Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, et al. 2006. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat. Chem. Biol. 2:434-41
120. Montrose DC, Scherl EJ, Bosworth BP, Zhou XK, Jung B, et al. 2013. S1P(1) localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity. J. Lipid Res. 54:843-51
121. Oskeritzian CA, Price MM, Hait NC, Kapitonov D, Falanga YT, et al. 2010. Essential roles of sphingosine-1-phosphate receptor 2 in human mast cell activation, anaphylaxis, and pulmonary edema. J. Exp. Med. 207:465-74
122. Olivera A, Dillahunt SE, Rivera J. 2013. Interrogation of sphingosine-1-phosphate receptor 2 function in vivo reveals a prominent role in the recovery from IgE and IgG-mediated anaphylaxis with minimal effect on its onset. Immunol. Lett. 150:89-96
123. Cui H, Okamoto Y, Yoshioka K, Du W, Takuwa N, et al. 2013. Sphingosine-1-phosphate receptor 2 protects against anaphylactic shock through suppression of endothelial nitric oxide synthase in mice. J. Allergy Clin. Immunol. 132:1205-1214.e9
124. Cruz-OrengoL,Daniels BP,DorseyD, Basak SA,Grajales-Reyes JG, et al. 2014. Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility. J. Clin. Investig. 124:2571-84
125. Kim GS, Yang L, Zhang G, Zhao H, Selim M, et al. 2015. Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke. Nat. Commun. 6:7893
126. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, et al. 2006. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355:1124-40
127. van Doorn R, Lopes Pinheiro MA, Kooij G, Lakeman K, van Hof B, et al. 2012. Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. J. Neuroinflamm. 9:133
128. Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS. 2012. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. PNAS 109:15930-35
129. Cartwright TA, Campos CR, Cannon RE, Miller DS. 2013. Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers. J. Cereb. Blood Flow Metab. 33:381-88
130. Herzog BH, Fu J,Wilson SJ, Hess PR, Sen A, et al. 2013. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature 502:105-9
131. Lorenz JN, Arend LJ, Robitz R, Paul RJ,MacLennan AJ. 2007. Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292:R440-46
132. Igarashi J, Michel T. 2009. Sphingosine-1-phosphate and modulation of vascular tone. Cardiovasc. Res. 82:212-20
133. Igarashi J, Bernier SG, Michel T. 2001. Sphingosine 1-phosphate and activation of endothelial nitricoxide synthase. differential regulation of Akt andMAP kinase pathways byEDGand bradykinin receptors in vascular endothelial cells. J. Biol. Chem. 276:12420-26
134. Morales-Ruiz M, Lee MJ, Zöllner S, Gratton JP, Scotland R, et al. 2001. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Giprotein/phosphoinositide 3-kinase pathway in endothelial cells. J. Biol. Chem. 276:19672-77
135. Kimura T, Sato K, Kuwabara A, Tomura H, IshiwaraM, et al. 2001. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 276:31780-85
136. Dantas AP, Igarashi J, Michel T. 2003. Sphingosine 1-phosphate and control of vascular tone. Am. J. Physiol. Heart Circ. Physiol. 284:H2045-52
137. Igarashi J, Miyoshi M, Hashimoto T, Kubota Y, Kosaka H. 2007. Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br. J. Pharmacol. 150:470-79
138. Cantalupo A, Zhang Y, Kothiya M, Galvani S, Obinata H, et al. 2015. Nogo-B regulates endothelial sphingolipid homeostasis to control vascular function and blood pressure. Nat. Med. 21:1028-37
139. Szczepaniak WS, Pitt BR, McVerry BJ. 2010. S1P2 receptor-dependent Rho-kinase activation mediates vasoconstriction in the murine pulmonary circulation induced by sphingosine 1-phosphate.Am. J. Physiol. Lung Cell. Mol. Physiol. 299:L137-45
140. Salomone S, Potts EM, Tyndall S, Ip PC, Chun J, et al. 2008. Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. Br. J. Pharmacol. 153:140-47
141. Guan Z, Singletary ST, Cook AK, Hobbs JL, Pollock JS, Inscho EW. 2014. Sphingosine-1-phosphate evokes unique segment-specific vasoconstriction of the renal microvasculature. J. Am. Soc. Nephrol. 25:1774-85
142. MacLennan AJ, Benner SJ, Andringa A, Chaves AH, Rosing JL, et al. 2006. The S1P2 sphingosine 1-phosphate receptor is essential for auditory and vestibular function. Hear. Res. 220:38-48
143. Herr DR, Grillet N, Schwander M, Rivera R, Müller U, Chun J. 2007. Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2. J. Neurosci. 27:1474-78
144. Kono M, Belyantseva IA, Skoura A, Frolenkov GI, StarostMF, et al. 2007. Deafness and stria vascularis defects in S1P2 receptor-null mice. J. Biol. Chem. 282:10690-96
145. Scherer EQ, Lidington D, Oestreicher E, Arnold W, Pohl U, Bolz SS. 2006. Sphingosine-1-phosphate modulates spiral modiolar artery tone:Apotential role in vascular-based inner ear pathologies? Cardiovasc. Res. 70:79-87
146. Chen J, Ingham N, Kelly J, Jadeja S, Goulding D, et al. 2014. Spinster homolog 2 (Spns2) deficiency causes early onset progressive hearing loss. PLOS Genet. 10:e1004688
147. Santos-Cortez RL, Faridi R, Rehman AU, Lee K, Ansar M, et al. 2016. Autosomal-recessive hearing impairment due to rare missense variants within S1PR2. Am. J. Hum. Genet. 98:331-38
148. Nofer JR, van der Giet M, Tölle M, Wolinska I, Wnuck Lipinski K, et al. 2004. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Investig. 113:569-81
149. Salomone S, Yoshimura S, Reuter U, Foley M, Thomas SS, et al. 2003. S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur. J. Pharmacol. 469:125-34
150. Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, et al. 2012. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has speciesspecific effects on heart rate. Br. J. Pharmacol. 167:1035-47
151. Legangneux E, Gardin A, Johns D. 2013. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br. J. Clin. Pharmacol. 75:831-41
152. Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG. 2008. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 28:122-33
153. Lo CG, Xu Y, Proia RL, Cyster JG. 2005. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J. Exp. Med. 201:291-301
154. Arnon TI, Xu Y, Lo C, Pham T, An J, et al. 2011. GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science 333:1898-903
155. Green JA, Suzuki K, Cho B,Willison LD, Palmer D, et al. 2011. The sphingosine 1-phosphate receptor S1P(2) maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat. Immunol. 12:672-80
156. Czeloth N, Bernhardt G, Hofmann F, Genth H, Förster R. 2005. Sphingosine-1-phosphate mediates migration of mature dendritic cells. J. Immunol. 175:2960-67
157. Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, et al. 2007. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat. Immunol. 8:1337-44
158. Jenne CN, Enders A, Rivera R,Watson SR, Bankovich AJ, et al. 2009. T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J. Exp. Med. 206:2469-81
159. Massberg S, Schaerli P, Knezevic-Maramica I, Köllnberger M, Tubo N, et al. 2007. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell 131:994-1008